Ascletis Announces U.S. IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors
- Sunday, February 6, 2022, 7:04
- Finance
- Add a comment
The objectives of the U.S. Phase I trial are to find a recommended Phase II dose and obtain preliminary efficacy in patients with advanced solid tumors The first U.S. patient is expected to be dosed in the first half of 2022 ASC61 shows significant antitumor efficacy as a single agent in…
About the Author
adminasapcorp has written 41552 stories on this site.